PATENT COOPERATION TREATY

o:			<u> </u>	PCT			
See form PCT/ISA/220 Applicant's or agent's file reference See form PCT/ISA/220				WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43 <i>bis</i> .1)			
				Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet)			
				FOR FURTHER ACTION See paragraph 2 below			
international application No. PCT/EP2004/009690		International filing date (d 31.08.2004	ay/month/year)	Priority date (day.monthyear) 01.09.2003			
			both national classification a	and IPC	•		
;07	D333/20, C07D3	U/ <i>1</i> 52					
• •	cant IZA AG						
.01	NZA AG						
		-t-i-a indiaati	and relating to the follo	owing items:			
•	This opinion contains indications relating to the following items:						
	☑ Box No. I	Basis of the or	oinion				
	☐ Box No. II	Priority					
	☑ Box No. III			ard to novelty, inventi	ve step and industrial applicability		
	☐ Box No. IV	Lack of unity of					
	Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
	☐ Box No. VI						
	Box No. VII		ts in the international app	dication			
		II Certain observations on the international application					
2.	FURTHER ACT						
- .	If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.						
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of the months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority whichever expires later.							
	For further options, see Form PCT/ISA/220.						
3.	For further details, see notes to Form PCT/ISA/220.						

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Steendijk, M

Telephone No. +49 89 2399-8460



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/009690

		{	Michiel Contract	24 3 2006			
	Box No	lo. I Basis of the opinion					
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.						
	lar	this opinion has been established on the basis of a tra anguage , which is the language of a translation funder Rules 12.3 and 23.1(b)).	anslation from the original I nished for the purposes of	anguage into the following international search			
2.	With re	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:					
	a. type	e of material:					
		a sequence listing					
		table(s) related to the sequence listing		•			
	b. form	mat of material:					
		in written format					
		in computer readable form					
	c. time	ne of filing/furnishing:					
		contained in the international application as filed.					
		filed together with the international application in ca	omputer readable form.				
		furnished subsequently to this Authority for the pur	rposes of search.				
3	h C	In addition, in the case that more than one version or has been filed or furnished, the required statements to copies is identical to that in the application as filed or appropriate, were furnished.	hat the information in the s	subsequent or acortional			
4	Additi	itional comments:					

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/009690

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
The questions whether the clair obvious), or to be industrially a	med invention appears to be novel, to involve an inventive step (to be non pplicable have not been examined in respect of:					
☐ the entire international app	the entire international application,					
⊠ claims Nos. 12						
because:						
the said international appliation does not require an international	the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):					
the description, claims or cunclear that no meaningfu	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):					
the claims, or said claims could be formed.	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.					
☐ no international search rep	no international search report has been established for the whole application or for said claims Nos. 12					
the nucleotide and/or amir C of the Administrative Ins	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:					
the written form	☐ has not been furnished					
	☐ does not comply with the standard					
the computer readable for	rm					
	☐ does not comply with the standard					
the tables related to the n not comply with the techn	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, or not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.					
☐ See senarate sheet for fu	rther details					

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/009690

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-11

No: Claims

Inventive step (IS)

Yes: Claims

No: Claims

1-11

Industrial applicability (IA)

Yes: Claims

1-11

No: Claims

2. Citations and explanations

see separate sheet

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

1) The present application relates to the preparation of chiral compounds of formula i by asymmetric hydrogenation of ketones of formula II in the presence of a transition meta complex with a chiral bidentate phosphine ligand (claims 1-11). Furthermore, certain compounds of formula I are claimed (claim 12). In view of a finding of non-unity, the following observations concern only the subject-matter of claims 1-11.

2) The following documents are referred to

D1: WO 03 062219 A

D2: WO 03 061825 A

D3: WO 03 061826 A

D4: ORGANIC LETTERS, vol. 2, no. 12, 2000, pages 1749-1751,

D5: CHEM, PHARM. BULL. vol. 43, no. 5, 1995, pages 748-753,

D6: WO 02 10113 A

3) Novelty

The claimed matter may be acknowledged novelty:

Document D1 describes a process for obtaining a compound of formula! by resolving the racemic compound.

Documents D2-D4 describe the asymmetric hydrogenation of ketones in the presence of a transition metal complex with a chiral bidentate phosphine ligand and a diamine; the ketones of formula II are not specifically mentioned.

Documents D5 and D6 describe the asymmetric hydrogenation of ketones in the presence of a transition metal complex with a chiral bidentate phosphine ligand; the ketones of formula II are not mentioned.

4) Inventive step

In view of Document D1 the problem to be solved may be seen in the provision of an alternative method for providing enantiomerically pure compounds of formula I. As solution to this problem the claimed matter would at present seem obvious to the person skilled in the art. Asymmetric synthesis is well established as alternative to resolving methods. The person skilled in the art would therefore consider application of successful approaches for asymmetric synthesis of structurally related compounds such as described in documents D2-D5, in which the asymmetric hydrogenation of

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/EP2004/009690

related ketones in the presence of a transition metal complex with a chiral bidentate phosphine ligand with (D2-D4) or without (D5) diamines is described.